Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 2/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.58 |
| ▸ | CCKAR | P32238 | 1/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 8/20 | 0.56 |
| ▸ | GHSR | Q92847 | 2/20 | 0.52 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.52 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614911 | 0.94 | KISS1R (0.55) | CCKBROPRD1CCKARKISS1RGHSR | |
| SCHEMBL30044908 | 0.91 | KISS1R (0.61) | KISS1R | |
| SCHEMBL29476441 | 0.91 | KISS1R (0.55) | OPRD1KISS1RGHSRNPBWR1IL23R | |
| SCHEMBL29476439 | 0.91 | KISS1R (0.55) | OPRD1KISS1RGHSRNPBWR1IL23R | |
| SCHEMBL30919236 | 0.90 | KISS1R (0.55) | KISS1RGHSR | |
| SCHEMBL30919241 | 0.90 | KISS1R (0.55) | KISS1RGHSR | |
| SCHEMBL29672131 | 0.90 | NPY1R (0.56) | KISS1RGHSR | |
| SCHEMBL30688662 | 0.90 | MMP1 (0.51) | KISS1RGHSR | |
| SCHEMBL30264824 | 0.90 | KISS1R (0.55) | KISS1RGHSRNPBWR1IL23R | |
| SCHEMBL30264955 | 0.90 | KISS1R (0.55) | KISS1RGHSRNPBWR1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025106751-A1 | COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | CCKBR 57/4885OPRD1 150/4885CCKAR 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.